ANDA 204846, held by Invagen Pharms. Atorvastatin Calcium.
As of Nov 16, 2026, ANDA 204846 (Atorvastatin Calcium), held by Invagen Pharms, was first approved by FDA on Jan 9, 2017, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 9, 2017 | Original application | Approved |
| Atorvastatin CalciumEQ 10MG BASE · tablet;oral | Atorvastatin Calcium | Discontinued |
| Atorvastatin CalciumEQ 20MG BASE · tablet;oral | Atorvastatin Calcium | Discontinued |
| Atorvastatin CalciumEQ 40MG BASE · tablet;oral | Atorvastatin Calcium | Discontinued |
| Atorvastatin CalciumEQ 80MG BASE · tablet;oral | Atorvastatin Calcium | Discontinued |
| Sep 22, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 22, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 22, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 22, 2026 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 9, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters